The effectiveness of allergen immunotherapy (AIT) in seasonal and perennial allergic rhinitis (AR) depends on the definition of pollen exposure intensity or time period. We recently evaluated pollen and symptom data from Germany to examine the new definitions of the European Academy of Allergy and Clinical Immunology (EAACI) on pollen season and peak pollen period start and end. Now, we aim to confirm the feasibility of these definitions to properly mirror symptom loads for grass and birch pollen‐induced allergic rhinitis in other European geographical areas such as Austria, Finland and France, and therefore their suitability for AIT and clinical practice support.

中文翻译：

---

花粉季节反映在不同地理区域草和桦树花粉引起的过敏性鼻炎的症状负荷上——EAACI 工作组报告

过敏原免疫疗法 (AIT) 在季节性和常年性过敏性鼻炎 (AR) 中的有效性取决于花粉暴露强度或时间段的定义。我们最近评估了来自德国的花粉和症状数据，以检查欧洲过敏和临床免疫学会 (EAACI) 关于花粉季节和花粉高峰期开始和结束的新定义。现在，我们的目标是确认这些定义的可行性，以正确反映其他欧洲地理区域（如奥地利、芬兰和法国）草和桦树花粉引起的过敏性鼻炎的症状负荷，因此它们适用于 AIT 和临床实践支持。